Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107634 | 0.92 | PTGS2 (0.56) | PTGS2ALOX5EPHX2PTGS1CA1 | |
| SCHEMBL1107632 | 0.88 | ALOX5 (0.50) | PTGS2ALOX5EPHX2PTGS1CA9 | |
| SCHEMBL12742800 | 0.74 | GRN (0.56) | PTGS2PTGS1 | |
| SCHEMBL1107515 | 0.71 | CA9 (0.58) | PTGS2CA9 | |
| SCHEMBL17369126 | 0.71 | ALDH1A1 (0.59) | — | |
| SCHEMBL17369124 | 0.71 | SMN1; SMN2 (0.57) | — | |
| SCHEMBL9941416 | 0.70 | ALOX5 (0.81) | PTGS2ALOX5EPHX2PTGS1CA1 | |
| SCHEMBL9941289 | 0.68 | PTGS2 (1.00) | PTGS2ALOX5EPHX2PTGS1CA1 | |
| SCHEMBL9941646 | 0.68 | ALOX5 (0.69) | PTGS2ALOX5EPHX2PTGS1CA1 | |
| SCHEMBL14562013 | 0.67 | PTGS2 (0.70) | PTGS2ALOX5EPHX2PTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | PTGS2 3999/4885ALOX5 3188/4885EPHX2 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.